Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

The second-quarter earnings season for the pharmaceutical and biotech sector is underway, with the broader Medical sector anticipating flat earnings but 8.7% sales growth and early reporters largely surpassing estimates. Pfizer, Eli Lilly, Amgen, and Gilead Sciences are generally expected to deliver strong Q2 results, propelled by key product lines such as Lilly's Mounjaro/Zepbound and Gilead's HIV portfolio. Conversely, Novo Nordisk recently lowered its 2025 sales growth outlook to 8-14% and operating profit to 10-16%, while missing preliminary Q2 EPS at $0.91 versus a $0.94 consensus, citing weaker momentum for its GLP-1 drugs, highlighting a significant divergence in performance expectations within the industry.

Analysis

The upcoming Q2 earnings for major pharmaceutical firms highlight a significant divergence in performance, particularly within the high-growth GLP-1 market. While the broader Medical sector has seen strong early reporters (95% beating revenue estimates), overall sector earnings are projected to be flat, creating a selective environment. Eli Lilly (LLY), Amgen (AMGN), and Gilead (GILD) are positioned for positive earnings surprises, supported by a Zacks Rank #3 and positive Earnings ESPs. Lilly's growth is expected to be propelled by robust demand for its GLP-1 drugs Mounjaro and Zepbound. Similarly, Gilead's HIV franchise, led by Biktarvy, and Amgen's volume growth in products like Evenity and Repatha are anticipated to drive strong results. In stark contrast, Novo Nordisk (NVO) has signaled significant headwinds, issuing a preliminary Q2 EPS of $0.91 which missed the $0.94 consensus, and materially lowering its 2025 guidance for sales growth to 8-14% (down from 13-21%) and operating profit growth to 10-16% (down from 16-24%), citing weaker momentum in its key GLP-1 drugs. This negative preannouncement, combined with a Zacks Rank #4 (Sell), creates a sharp juxtaposition with Lilly's expected strength and raises critical questions about market saturation or a potential market share shift in the obesity and diabetes space. Meanwhile, Pfizer (PFE) faces a mixed outlook, with growth from newer products like Vyndaqel potentially being offset by declines in legacy drugs and pricing pressures from the Inflation Reduction Act.

Key Decisions for Investors

• Investors should closely watch Eli Lilly's upcoming earnings for confirmation of strong Mounjaro and Zepbound sales, as this will be critical to determine if Novo Nordisk's weakness is a company-specific issue or the beginning of a broader GLP-1 market slowdown.
• The diverging outlooks between Eli Lilly and Novo Nordisk could present a relative value or pairs trade opportunity, favoring long positions in LLY against short positions in NVO, pending confirmation from their respective earnings calls.
• Consider the relative stability of diversified biopharmas like Amgen and Gilead, whose growth is driven by multiple products across different therapeutic areas, potentially offering a buffer against the pricing pressures and intense competition seen in specific drug classes.
• For Pfizer, it is crucial to assess whether the growth contribution from its newer products is sufficient to outpace the erosion of its legacy portfolio and the margin impact of the Inflation Reduction Act.